New Software May Improve Stroke Treatment Trial Selection
Automated imaging analysis could help identify candidates for investigational stroke therapies without complex scans.
Updated on Oct. 28, 2026 in Stroke
Live Poll
Should doctors trust AI analysis over advanced imaging when selecting patients for clinical trials?
Researchers have identified a potential method for selecting stroke patients for therapy trials using standard imaging software. By analyzing brain infarct volumes, this approach could streamline future testing for the investigational drug glyburide, also known as Cirara.
Why it matters
Currently, trial selection often requires complex imaging like CT perfusion or MRI, which can be inaccessible in some settings. Simplifying this process with noncontrast CT scans could expand participation and speed up the evaluation of potential stroke treatments.
This post-hoc analysis of the phase III Charm trial evaluated 428 patients, finding that those with infarct core volumes below 125 mL showed improved 90-day functional outcomes when treated with glyburide. The findings are preliminary and require further validation in clinical settings.
The players
Brainomix
A medical imaging company specializing in software tools that automate the interpretation of stroke-related brain scans.
Remedy Pharmaceuticals
A biotechnology firm developing Cirara, an investigational therapy currently being studied for its potential in stroke management.
The details
The software uses automated noncontrast CT analysis to measure the acute infarct volume, which helps identify patients with large hemispheric infarction. By focusing on this specific volume threshold, clinicians may be able to identify individuals most likely to respond to Cirara. This investigational therapy is designed to address brain swelling, though it has not yet received regulatory approval for clinical use.
Timeline
90 days post-stroke was the timeframe used for assessing functional outcomes on the modified Rankin Scale.
Health Landscape
This analysis builds upon the legacy of the phase III Charm trial to refine how stroke candidates are selected for emerging therapies. It represents a broader shift toward using automated software to maximize the utility of standard diagnostic imaging in urgent care settings.
These findings are strictly for use in clinical research trials and do not change current treatment protocols for stroke patients. If you or a loved one are considering enrollment in a clinical trial, it is a conversation to have with your neurologist regarding eligibility criteria.
The takeaway
While this software-based selection method is promising for trial efficiency, it remains an experimental approach. Patients interested in novel stroke therapies should focus on discussing current clinical trial opportunities with a specialist in stroke neurology.
Further reading
Learn more about ongoing research into Stroke and new diagnostic approaches.
Source note: This article includes information reported by AuntMinnie.
Live Poll
Should doctors trust AI analysis over advanced imaging when selecting patients for clinical trials?
